Search

Brightline-2 clinical trial is studying our investigational MDM2-p53 antagonist for people with advanced cancer in the biliary tract or pancreatic cancer.

ATS Announces that BI is First Donor of COVID-19 Fund | Boehringer Ingelheim US

American Thoracic Society Announces that Boehringer Ingelheim is the first donor of its COVID‐19 Crisis Fund

New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations

When Passion Starts as a Family Value and Continues as a Work Value

Discover who inspires members of our LatinX Business Resource Group.

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®

Nintedanib Study: Systemic Sclerosis & Lung Fibrosis | Boehringer Ingelheim US

Boehringer Ingelheim today announced that the first patient was enrolled in the SENSCIS™ (Safety and Efficacy of Nintedanib in SystemicSClerosIS) study.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Actress Angela Bassett joins For Your SweetHeart™ to urge people with diabetes to know their heart disease risk — in honor of her mom

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound

Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious Diseases

Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform

Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance

Pushing for Progress

FDA approves Gilotrif® (afatinib) in EGFR NSCLC | Boehringer Ingelheim US

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors

Jardiance® (empagliflozin) analysis reinforces established safety profile

U.S. FDA approves Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes

Boehringer Ingelheim Launches Observational Study on Management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate mesylate)

From garbage to garden - Recycling organic waste to contribute to a healthier planet

Boehringer Ingelheim Partners with Express Scripts on their Patient Assurance Program Expansion for People with Type 2 Diabetes

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

BI & Lilly to Assess Jardiance® (empagliflozin) & Heart Failure | Boehringer Ingelheim US

Boehringer Ingelheim and Lilly expand heart failure program for Jardiance with new exercise capacity trials

Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors

Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway

New Long-Term Data Published in Circulation Reinforce Safety Profile of Pradaxa® (dabigatran etexilate mesylate)

Bringing focus to unmet needs in biliary tract and pancreatic cancer with the Brightline-2 Trial

ATS Announces that BI is First Donor of COVID-19 Fund | Boehringer Ingelheim US

New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations

When Passion Starts as a Family Value and Continues as a Work Value

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®

Nintedanib Study: Systemic Sclerosis & Lung Fibrosis | Boehringer Ingelheim US